Nano to micro delivery systems: targeting angiogenesis in brain tumors

Abstract

Treating brain tumors using inhibitors of angiogenesis is extensively researched and tested in clinical trials. Although anti-angiogenic treatment holds a great potential for treating primary and secondary brain tumors, no clinical treatment is currently approved for brain tumor patients. One of the main hurdles in treating brain tumors is the blood brain barrier - a protective barrier of the brain, which prevents drugs from entering the brain parenchyma. As most therapeutics are excluded from the brain there is an urgent need to develop delivery platforms which will bypass such hurdles and enable the delivery of anti-angiogenic drugs into the tumor bed. Such delivery systems should be able to control release the drug or a combination of drugs at a therapeutic level for the desired time. In this mini-review we will discuss the latest improvements in nano and micro drug delivery platforms that were designed to deliver inhibitors of angiogenesis to the brain.

How Precise are Nanomedicines in Overcoming the Blood–Brain Barrier? A Comprehensive Review of the Literature

“……”

How Precise are Nanomedicines in Overcoming the Blood–Brain Barrier? A Comprehensive Review of the Literature

“……”

Lab-On-A-Chip for the Development of Pro-/Anti-Angiogenic Nanomedicines to Treat Brain Diseases

“…(see Table 1). Only a few are FDA approved-namely, lomustine-liposomes and carboplatin-liposomes-and the survival benefits are very limited [25]. While NMs aid in overcoming the anatomical barriers, most of the NM's clinical viability is still unclear due to the lack of suitable pre-clinical models for drug screening.The disproportionate and expensive failures during the clinical transformation of the angiogenic brain drugs, have led to the divestment in brain drug development [26].…”

“…(see Table 1). Only a few are FDA approved-namely, lomustine-liposomes and carboplatin-liposomes-and the survival benefits are very limited [25]. While NMs aid in overcoming the anatomical barriers, most of the NM's clinical viability is still unclear due to the lack of suitable pre-clinical models for drug screening.…”

Nano carriers for drug transport across the blood–brain barrier

“……”

How Precise are Nanomedicines in Overcoming the Blood–Brain Barrier? A Comprehensive Review of the Literature

“……”

Lab-On-A-Chip for the Development of Pro-/Anti-Angiogenic Nanomedicines to Treat Brain Diseases

“…(see Table 1). Only a few are FDA approved-namely, lomustine-liposomes and carboplatin-liposomes-and the survival benefits are very limited [25]. While NMs aid in overcoming the anatomical barriers, most of the NM's clinical viability is still unclear due to the lack of suitable pre-clinical models for drug screening.The disproportionate and expensive failures during the clinical transformation of the angiogenic brain drugs, have led to the divestment in brain drug development [26].…”

“…(see Table 1). Only a few are FDA approved-namely, lomustine-liposomes and carboplatin-liposomes-and the survival benefits are very limited [25]. While NMs aid in overcoming the anatomical barriers, most of the NM's clinical viability is still unclear due to the lack of suitable pre-clinical models for drug screening.…”

Nano carriers for drug transport across the blood–brain barrier

“……”

How Precise are Nanomedicines in Overcoming the Blood–Brain Barrier? A Comprehensive Review of the Literature

“……”

Lab-On-A-Chip for the Development of Pro-/Anti-Angiogenic Nanomedicines to Treat Brain Diseases

“…(see Table 1). Only a few are FDA approved-namely, lomustine-liposomes and carboplatin-liposomes-and the survival benefits are very limited [25]. While NMs aid in overcoming the anatomical barriers, most of the NM's clinical viability is still unclear due to the lack of suitable pre-clinical models for drug screening.The disproportionate and expensive failures during the clinical transformation of the angiogenic brain drugs, have led to the divestment in brain drug development [26].…”

“…(see Table 1). Only a few are FDA approved-namely, lomustine-liposomes and carboplatin-liposomes-and the survival benefits are very limited [25]. While NMs aid in overcoming the anatomical barriers, most of the NM's clinical viability is still unclear due to the lack of suitable pre-clinical models for drug screening.…”

Nano carriers for drug transport across the blood–brain barrier

“……”